Pharmacodynamics of Rituximab in Kidney Allotransplantation
| Autor: | A Hansson, Helena Genberg, Annika Wernerson, Gunnar Tydén, L Wennberg |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Graft Rejection medicine.medical_specialty Pathology Biopsy medicine.medical_treatment Lymphocyte Antigens CD19 Gastroenterology Antibodies Monoclonal Murine-Derived hemic and lymphatic diseases Internal medicine medicine Humans Immunologic Factors Transplantation Homologous Immunology and Allergy Pharmacology (medical) Child Lymph node Kidney transplantation Retrospective Studies CD20 B-Lymphocytes Transplantation Kidney biology business.industry Antibodies Monoclonal Immunosuppression Antigens CD20 Flow Cytometry medicine.disease Kidney Transplantation Treatment Outcome medicine.anatomical_structure biology.protein Rituximab Lymph Nodes business Follow-Up Studies Allotransplantation medicine.drug |
| Zdroj: | American Journal of Transplantation. 6:2418-2428 |
| ISSN: | 1600-6135 |
| DOI: | 10.1111/j.1600-6143.2006.01497.x |
| Popis: | The anti-CD20 antibody rituximab has recently gained interest as a B-cell depleting agent in renal transplantation. However, little is known about the pharmacodynamics of rituximab in renal transplant recipients. We have therefore studied the effect of single-dose rituximab in combination with conventional triple immunosuppressive therapy on the B-cell population in peripheral blood as well as in tissues. A total of 49 renal transplant recipients received single-dose rituximab, as induction therapy (n = 36) or as anti-rejection therapy (n = 13). We counted B cells in peripheral blood and performed immunohistochemical staining on lymph nodes and kidney transplant tissue samples to assess the prevalence of B cells. In all but 6 patients (88%) complete depletion of B cells in peripheral blood was achieved. In adults, 15 months after treatment the CD19+ and CD20+ cell counts were still below 5 cells/muL in the majority of patients (78%). The immunohistochemical staining showed a complete elimination of B cells in kidney tissue and a reduction of B cells in lymph nodes. In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B cells in peripheral blood as well as within the kidney transplant. The effect seems to extend beyond the expected 3-12 months observed in lymphoma patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text